Abivax (NASDAQ:ABVX – Get Free Report)‘s stock had its “buy” rating restated by equities research analysts at Guggenheim in a research note issued on Tuesday, Benzinga reports. They presently have a $175.00 price target on the stock. Guggenheim’s price objective would suggest a potential upside of 95.47% from the company’s current price.
Several other analysts also recently weighed in on ABVX. The Goldman Sachs Group began coverage on Abivax in a report on Wednesday, September 9th. They issued a “buy” rating and a $155.00 target price for the company. Truist Financial dropped their price target on Abivax from $155.00 to $151.00 and set a “buy” rating on the stock in a research note on Tuesday, September 22nd. Morgan Stanley reaffirmed an “overweight” rating and set a $180.00 price target on shares of Abivax in a research report on Friday, July 24th. Barclays reiterated an “overweight” rating and issued a $148.00 price objective on shares of Abivax in a research note on Tuesday, September 22nd. Finally, Jefferies Financial Group raised Abivax from a “hold” rating to a “buy” rating and increased their price objective for the company from $108.00 to $158.00 in a report on Tuesday, June 30th. One equities research analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $156.69.
View Our Latest Stock Analysis on Abivax
Abivax Trading Up 2.3%
Shares of NASDAQ:ABVX opened at $89.53 on Tuesday. The company has a market capitalization of $7.84 billion, a PE ratio of -14.74 and a beta of 1.14. Abivax has a twelve month low of $69.81 and a twelve month high of $148.83. The firm has a 50 day simple moving average of $105.79 and a 200-day simple moving average of $114.49.
Abivax (NASDAQ:ABVX – Get Free Report) last announced its quarterly earnings results on Monday, September 21st. The company reported ($1.71) EPS for the quarter, missing the consensus estimate of ($0.92) by ($0.79). The company had revenue of $1.37 million for the quarter, compared to analysts’ expectations of $0.80 million. As a group, equities research analysts predict that Abivax will post -4.04 EPS for the current fiscal year.
Institutional Investors Weigh In On Abivax
Hedge funds and other institutional investors have recently modified their holdings of the stock. Vontobel Holding Ltd. lifted its holdings in shares of Abivax by 20.9% in the third quarter. Vontobel Holding Ltd. now owns 4,167 shares of the company’s stock valued at $413,000 after purchasing an additional 719 shares in the last quarter. Goldstein Advisors LLC increased its stake in shares of Abivax by 49.6% during the 3rd quarter. Goldstein Advisors LLC now owns 2,390 shares of the company’s stock worth $237,000 after purchasing an additional 792 shares in the last quarter. Sax Wealth Advisors LLC acquired a new position in shares of Abivax during the 3rd quarter worth approximately $642,000. Avior Wealth Management LLC lifted its stake in Abivax by 17.9% in the 3rd quarter. Avior Wealth Management LLC now owns 3,581 shares of the company’s stock valued at $355,000 after buying an additional 544 shares in the last quarter. Finally, Vilga Financial Planning LLC purchased a new stake in Abivax in the 3rd quarter valued at approximately $2,178,000. 47.91% of the stock is currently owned by institutional investors and hedge funds.
Abivax Company Profile
Abivax SA (NASDAQ: ABVX) is a clinical-stage biotechnology company focused on developing therapeutics for chronic inflammatory and immune-mediated diseases. Headquartered in Paris, France, the company conducts research and clinical development aimed at addressing conditions with significant unmet medical needs.
Abivax’s lead investigational product is obefazimod, an oral small-molecule therapy designed to selectively increase levels of microRNA-124, a regulatory molecule involved in controlling inflammatory responses.
Featured Articles
- Five stocks we like better than Abivax
- Wired for Upside: Why Goldman Sachs Upgraded CoreWeave’s Battered Stock
- CarMax’s Double Upgrade Could Signal a Bigger Turnaround
- EHang’s 160% Call Options Surge: What Are Traders Seeing?
- D-Wave Stock Has 2 New Reasons for Investors to Pay Attention
Receive News & Ratings for Abivax Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abivax and related companies with MarketBeat.com's FREE daily email newsletter.
